Results 11 to 20 of about 100,010 (342)
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez +3 more
doaj +4 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Biomedicines, 2016 Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell.
Adam C. Parslow +4 more
doaj +4 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
+8 more sources
Antibody-Drug Conjugates [PDF]
Pharmaceutical Research, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni +1 more
+7 more sources
Practical oncology, 2023 This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova +2 more
+5 more sources
Antibody-Drug Conjugates [PDF]
Journal of Nihon University Medical Association, 2017 Abstract Antibody–drug conjugates (ADCs) are designed with the purpose of delivering small-molecule cytotoxic drug to antigen-expressing tumor cells by harnessing the specificity, biodistribution, and pharmacokinetics of antibodies. ADCs are comprised of three components: the antibody, the linker, and the cytotoxic agent.
Amit Kumar +4 more
+5 more sources
Resistance to Antibody–Drug Conjugates [PDF]
Cancer Research, 2018 Abstract Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent.
García-Alonso, Sara +2 more
openaire +3 more sources
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]
, 2016 First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa +11 more
core +5 more sources
Antibody Conjugation and Formulation [PDF]
, 2019 In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market the formulation demands for ...
Alves, Nathan J.
core +1 more source